The classical pathway is one of three activation routes in the complement system, a network of roughly 30 blood proteins that work together to destroy pathogens. It begins when a large recognition molecule called C1q locks onto antibodies clustered on a target surface, setting off a chain of protein-clipping events that ultimately punch holes in invading cells, recruit immune cells to the site, and tag debris for cleanup. What makes this pathway “classical” is simply that it was discovered first, but its dependence on antibody recognition also makes it a crucial bridge between the adaptive immune response and the rapid, innate killing machinery of complement.
The C1 Complex and How It Recognizes a Target
Everything starts with C1, a large protein complex that floats in the blood waiting for a signal. C1 is built from three components: C1q, the recognition piece, and a cluster of four protease enzymes arranged as two copies each of C1r and C1s. Together, the whole assembly weighs about 774 kilodaltons and requires calcium ions to hold its shape.1PubMed Central. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade C1q looks a bit like a bouquet of six tulips: six globular “heads” fan out from a collagen-like stalk, and each head can independently grab onto a target. The C1r and C1s proteases sit nestled between those stems, ready to activate the moment C1q changes shape.2PubMed Central. Structure of the C1r-C1s interaction of the C1 complex of complement activation
C1q’s favorite target is a cluster of IgG or IgM antibodies sitting on a pathogen or damaged cell. A single antibody molecule floating alone barely registers, but when several IgG molecules gather tightly on a surface, they form hexameric rings of six antibodies. Structural studies using mass spectrometry have shown that C1q binds to these hexamers at a one-to-one ratio: one C1q molecule per ring of six antibodies. Antibody variants that cannot form hexamers in solution fail to bind C1q at all, confirming that this clustering is a requirement for activation rather than a nice-to-have.3Molecular Cell. Insights into Complement Activation by Reconstitution of C1 bound to Antigen-Housed IgG Hexamers This design is elegant: it ensures that complement does not fire on a lone antibody drifting through plasma, only on surfaces densely coated with antibodies.
Triggers That Do Not Involve Antibodies
Although antibody-bound targets are the textbook trigger, C1q is not exclusively an antibody sensor. C-reactive protein (CRP), an acute-phase protein whose blood levels spike during infection and inflammation, also activates the classical pathway. CRP binds to phosphocholine molecules exposed on damaged membranes and on the surfaces of some bacteria. Once CRP is sitting on a membrane, C1q recognizes it through the same globular head region it uses for antibodies, launching the same downstream cascade.4PubMed. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region Cryo-electron tomography has recently provided a structural picture of how CRP, bound to phosphocholine on a membrane surface, docks with the C1 complex.5PubMed Central. Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein This means the classical pathway can activate before the adaptive immune system even produces specific antibodies, as long as CRP or similar danger-sensing molecules are present.
The Proteolytic Chain Reaction
Once C1q binds its target and changes shape, C1r activates itself and then clips C1s into its active form. Active C1s is the workhorse enzyme that kicks off the real cascade. It first cuts complement protein C4 into two pieces: a small fragment, C4a, that drifts away, and a larger, chemically reactive fragment, C4b, that sticks to the nearby surface. C4b then grabs complement protein C2 out of the blood. C1s cuts C2 as well, releasing a small piece (C2b) and leaving the active enzyme fragment C2a attached to C4b. The result, called C4b2a, is the classical pathway’s C3 convertase: the enzyme that cleaves the most important protein in the entire complement system, C3.6PubMed Central. Solution Structures of Complement C2 and Its C4 Complexes Propose Pathway-specific Mechanisms for Control and Activation of the Complement Proconvertases
C4b2a is powerful but short-lived. At body temperature, the C2a piece falls off the C4b anchor rapidly, and the enzyme dies. Kinetic measurements put this decay rate at about 2 min⁻¹ at 37 °C, meaning the enzyme’s active life is measured in seconds, not minutes.7PubMed Central. The human complement system: assembly of the classical pathway C3 convertase That built-in instability is a safety feature: it ensures that complement activity stays focused on the spot where C1 originally bound rather than spreading to healthy tissue.
While C4b2a lasts, it cleaves C3 molecules into C3a and C3b fragments. C3b is the pivotal molecule. Some of it binds covalently to the target surface (opsonization), and some of it binds directly to C4b2a itself. When C3b joins the C4b2a complex, the result is a three-protein assembly, C4b2a3b, known as the classical pathway’s C5 convertase.8PubMed. Localization of the covalent C3b-binding site on C4b within the complement classical pathway C5 convertase, C4b2a3b This enzyme cleaves C5 into C5a and C5b, and with that, the pathway hands off to the terminal sequence that builds the membrane attack complex.
Three Jobs the Pathway Accomplishes
The cascade generates several products, each with a distinct function. Those functions are the practical reason complement exists.
- Inflammation signals: The small fragments released during cleavage, especially C3a and C5a, are anaphylatoxins. They bind to receptors on immune cells at very low concentrations and trigger inflammation: blood vessels become leaky, smooth muscle contracts, and white blood cells rush to the area.9PubMed. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses C5a is the more potent of the two and also shapes adaptive immune responses, though overactivation of these signals contributes to tissue damage in autoimmune and inflammatory diseases.10PubMed Central. Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease
- Opsonization: C3b molecules deposited on a pathogen’s surface act as “eat me” tags. Immune cells such as neutrophils carry complement receptors that recognize C3b and pull the coated microbe in for destruction. In experiments with bacteria coated in purified C3b, blocking complement receptor 1 on neutrophils substantially reduced phagocytosis, confirming that C3b coating is not just decorative.11PubMed Central. Purified complement C3b triggers phagocytosis and activation of human neutrophils via complement receptor 1 Studies of people with deficiencies in classical pathway components (like C2) show impaired C3b deposition on pneumococcal bacteria and reduced ability to phagocytose them, underscoring how dependent this tagging process is on the classical route.12PubMed Central. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway
- Direct killing: Once C5b is generated, it recruits C6, C7, C8, and multiple copies of C9 to assemble the membrane attack complex (MAC). The MAC forms a pore in the target cell’s membrane, letting water and ions rush in until the cell bursts.13PubMed Central. Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets If fewer pores form (sublytic levels), they do not kill the cell outright but instead activate signaling pathways inside it, which can trigger inflammation or other responses.14Nature Communications. Structural basis of complement membrane attack complex formation
How the Body Keeps the Pathway in Check
A system this destructive needs tight regulation, and the body uses several brakes at different points in the cascade. The most important early check is C1 inhibitor (C1-INH), a protein that physically grabs and shuts down both C1r and C1s, preventing any further cleavage of C4 and C2. C1-INH is the primary regulator of both classical pathway activation and the kinin system, which controls blood-vessel permeability. Further downstream, the C3 convertase C4b2a is regulated in at least three ways: its own intrinsic instability (the rapid decay already described), an accelerated disassembly driven by a blood protein called C4b-binding protein, and the outright destruction of C4b by an enzyme that clips its chain into inactive fragments.15PubMed Central. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase Together, these mechanisms ensure that complement chews through invaders but does not linger on healthy tissue.
The Amplification Loop
The classical pathway does not work in isolation. Once C3b lands on a surface, it can recruit factor B from the blood. Factor D then cleaves factor B, creating an alternative pathway C3 convertase (C3bBb) that generates even more C3b. This alternative pathway amplification loop means that a small initial deposit of C3b from the classical pathway can snowball into heavy surface coating.16PubMed Central. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation In most encounters with microbes, the alternative pathway is serving mainly as an amplifier of C3b that the classical pathway deposited first.17PubMed. Alternative pathway amplification and infections The additional C3b also feeds into the alternative pathway’s own C5 convertase, meaning that C5 cleavage and MAC assembly accelerate as well. In practical terms, the classical pathway lights the match, and the alternative pathway fans it into a blaze.
What Happens When the Classical Pathway Breaks Down
Genetic deficiencies in any early classical pathway component carry surprisingly specific clinical consequences. The most dramatic example involves C1q itself. People born without functional C1q are strongly predisposed to developing systemic lupus erythematosus (SLE), the prototypical autoimmune disease of immune-complex deposition.18PubMed Central. C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus Deficiencies of C4 and C2 carry the same risk, though to a somewhat lesser degree. The likely explanation is that without a functioning classical pathway, the body cannot efficiently clear immune complexes or clean up dying cells. The debris accumulates, the immune system sees it as foreign, and autoimmunity follows.19PubMed. Complement deficiencies and systemic lupus erythematosus
A different kind of problem arises when the main regulator of C1 goes missing. C1-INH deficiency causes hereditary angioedema (HAE), a condition marked by unpredictable episodes of severe swelling in the skin, gut, or airway. The swelling is not driven by complement damage directly but rather by the overproduction of bradykinin, a peptide that makes blood vessels leak fluid. Because C1-INH normally restrains both the complement and kinin pathways, losing it causes both systems to run unchecked.20PubMed. C1 inhibitor: from complement system to bradykinin angioedema HAE can be inherited through a mutation in the SERPING1 gene or acquired later in life, often in the context of lymphoproliferative disease. Measuring C1-INH levels and function remains the standard diagnostic test.21PubMed Central. The Role of Bradykinin Receptors in Hereditary Angioedema Due to C1-Inhibitor Deficiency
Drugs That Target the Classical Pathway
Because the classical pathway can cause harm when it fires against the body’s own cells, selectively blocking it is a growing area of drug development. The clearest success so far is sutimlimab, a monoclonal antibody that binds and inhibits C1s, the protease responsible for cutting C4 and C2. By blocking C1s, sutimlimab shuts down the classical pathway without touching the alternative or lectin routes, preserving much of the body’s complement-mediated defense against infections.22PubMed. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
Sutimlimab was approved for cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia in which antibodies coat red blood cells at cold temperatures, triggering the classical pathway to destroy them. The approval was based on a phase III trial that showed rapid improvement in hemolysis markers, hemoglobin levels, and fatigue, with low toxicity.23PubMed. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis The drug’s specificity for the classical pathway makes it a proof of concept that you can surgically block one complement branch while leaving the others to handle microbial threats.
How Pathogens Fight Back
Given how lethal complement can be, it is no surprise that bacteria, viruses, fungi, and parasites have all evolved ways to dodge it. Some bacteria produce proteins that bind C1q and prevent it from activating C1r and C1s. Others coat themselves in host regulatory molecules so that complement sees them as “self.” Viruses sometimes steal genes for complement-regulating proteins from their hosts and express them on their own envelopes. The range of evasion tactics is enormous, spanning every step of the cascade and every major pathogen group.24PubMed Central. Microbial evasion of the complement system: a continuous and evolving story This arms race is part of why the complement system has so many overlapping pathways: if a pathogen learns to block one route, the other two can still respond.
Complement Proteins in the Brain
One of the more surprising findings in recent immunology is that C1q, C3, and C4 play a role entirely outside infection. During brain development, the nervous system produces far more synaptic connections between neurons than it ultimately needs. The weaker or redundant connections have to be pruned away, and it turns out that classical pathway complement proteins are part of how the brain decides which synapses to cut. C1q and downstream C3 tag unwanted synapses, and specialized brain immune cells called microglia, which are in a highly active state during the pruning window, engulf and destroy the tagged connections.25PubMed. Complement System in Neural Synapse Elimination in Development and Disease
This process is normally limited to early development, but in neurodegenerative diseases like Alzheimer’s, complement proteins become profoundly upregulated in the brain well before neurons start dying. The working hypothesis is that the same molecular machinery that helpfully pruned synapses during childhood is reactivated inappropriately, driving synapse loss and cognitive decline in the adult brain.26PubMed. The complement system: an unexpected role in synaptic pruning during development and disease Research into whether blocking complement in the brain could slow neurodegeneration is still early, but the finding has fundamentally changed how scientists think about the relationship between immunity and brain function.
Evolutionary Origins of C1q
If the classical pathway depends on antibodies, and antibodies did not appear until jawed vertebrates evolved roughly 450 million years ago, what was C1q doing before that? The answer comes from lampreys, jawless fish that split from the vertebrate lineage long before antibodies existed. Lampreys have a C1q-like protein, but instead of recognizing antibodies, it functions as a lectin, binding directly to sugar molecules like N-acetylglucosamine on microbial surfaces. Lamprey C1q also pairs with a protease from the same enzyme family as mammalian C1r and C1s, and that protease can cleave lamprey C3.27PubMed Central. Origin of the classical complement pathway: Lamprey orthologue of mammalian C1q acts as a lectin In other words, the pathway existed in a recognizable form before antibodies did. C1q started as a pattern-recognition molecule in innate immunity and was later co-opted to serve as an antibody sensor once adaptive immunity came along.
Even more intriguing, a C1q-like protein identified in amphioxus, a small marine animal that diverged from vertebrates even earlier, can bind human IgG and activate classical pathway complement in laboratory experiments. That result suggests the capacity of the C1q family to interact with immunoglobulin-like molecules may be ancient, predating anything we would normally call an antibody.28PubMed. An amphioxus gC1q protein binds human IgG and initiates the classical pathway: Implications for a C1q-mediated complement system in the basal chordate The evolutionary story complicates the neat textbook narrative that “the lectin pathway came first and the classical pathway evolved from it.” The amphioxus data suggest the two routes may have a more intertwined and parallel history than anyone initially expected.